

What is claimed is:

1. A chimeric ligand protein in the form of a fusion polypeptide of a single-chain antibody (ScFv) specific for a surface antigen of tumor associated glycoprotein 72 (Tag-72) and gibbon ape leukemia virus (GaLV) envelope glycoprotein.
2. The chimeric ligand protein of claim 1, wherein the ScFv is inserted between the 199<sup>th</sup> and 200<sup>th</sup> amino acid residues of a surface subunit of GaLV envelope glycoprotein.
3. The chimeric ligand protein of claim 1, which has the amino acid sequence of SEQ ID NO: 9.
4. A gene encoding the chimeric ligand protein of claim 1.
5. The gene of claim 4, which has the nucleotide sequence of SEQ ID NO: 8.
6. A recombinant expression vector containing the gene of claim 4.
7. The recombinant expression vector of claim 6, which is pHEFvGEL199 (Accession No: KCTC-10596BP).
8. A packaging cell line transduced with the recombinant expression vector of claim 6.
9. A recombinant retrovirus produced by the packaging cell line of claim 8, wherein the chimeric ligand is distributed on its outer membrane.
10. An anti-cancer agent composition comprising the chimeric ligand of claim 1 as an effective ingredient and a pharmaceutically acceptable carrier.